The US Food and Drug Administration has issued a set of proposals intended to update the agency’s guidance on its breakthrough devices program, which is a voluntary program that allows enhanced review of medical devices that provide more effective treatment or diagnosis of life-threatening or debilitating diseases.
The proposals in the 21 October draft guidance "Select Updates for the Breakthrough Devices Program Guidance: Reducing Disparities in Health and Health Care," are intended to update the agency’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?